Well-endowed individuals and companies all over the world have spent a huge amount of resources in the quest to find a lasting remedy for diseases that have ravaged humanity. In this light, Seattle Genetics is one of the biotechnology entities whose efforts are aimed at developing antibody-based therapies that improve the management of cancer. Behind this reputable company is Clay Siegall who serves as the Seattle Genetics’ President, CEO, and Chairman of the Board.
In his mission of searching for a treatment option that can effectively manage cancer, Siegall co-founded Seattle Genetics in 1998. His education and strong research experience made it practical for Dr. Clay to keep up the fight until a promising solution was discovered. With six years of experience at Bristol-Myers Squibb Pharmaceutical Research Institute and a stint at the National Cancer Institute from 1988 to 1991, Siegall qualified as the best candidate for the inception of Seattle Genetics. Alongside leading Seattle Genetics, Dr. Clay is on the steering boards of Alder Bio-pharmaceuticals, Mirna Therapeutics, and Ultragenyx Pharmaceuticals.
With a focus on research and innovate modern cancer therapies, Siegall’s efforts are backed by scientific advancement, arduous research and best practices in drug development. There are no doubts about clay’s firm education background, extensive experience, and noteworthy accomplishments. He graduated from George Washington University where he earned a Ph.D. in Genetics. He is a holder of a Bachelor of Science in Zoology from the University of Maryland.
Dr. Clay’s efforts have earned him many accolades and several respectable awards. For instance, he was honored in 2013 with the University of Maryland Alumnus of the Year for Computer, Mathematics and Natural Sciences Award. Previously, in 2012, he earned the famous Pacific Northwest Ernst & Young Entrepreneur of the Year Award.
Besides his leadership roles and dedicated fight against cancer, Siegall is an accomplished author with more than 70 scientific publications to his name. Even with his tight schedules and extensive research efforts, Dr. Siegall has been leading Seattle Genetics funding campaigns that have borne more than a billion dollars. Additionally, he is also an astute business professional who steered his company through the initial public offering in 2001 to obtain sufficient finances for cancer research.